Guezour, N.; Soussi, G.; Brosseau, S.; Abbar, B.; Naltet, C.; Vauchier, C.; Poté, N.; Hachon, L.; Namour, C.; Khalil, A.;
et al. Grade 3–4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study. Cancers 2022, 14, 3878.
https://doi.org/10.3390/cancers14163878
AMA Style
Guezour N, Soussi G, Brosseau S, Abbar B, Naltet C, Vauchier C, Poté N, Hachon L, Namour C, Khalil A,
et al. Grade 3–4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study. Cancers. 2022; 14(16):3878.
https://doi.org/10.3390/cancers14163878
Chicago/Turabian Style
Guezour, Nadia, Ghassen Soussi, Solenn Brosseau, Baptiste Abbar, Charles Naltet, Charles Vauchier, Nicolas Poté, Lorry Hachon, Céline Namour, Antoine Khalil,
and et al. 2022. "Grade 3–4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study" Cancers 14, no. 16: 3878.
https://doi.org/10.3390/cancers14163878
APA Style
Guezour, N., Soussi, G., Brosseau, S., Abbar, B., Naltet, C., Vauchier, C., Poté, N., Hachon, L., Namour, C., Khalil, A., Trédaniel, J., Zalcman, G., & Gounant, V.
(2022). Grade 3–4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study. Cancers, 14(16), 3878.
https://doi.org/10.3390/cancers14163878
